US3614955A - Standby defibrillator and method of operation - Google Patents

Standby defibrillator and method of operation Download PDF

Info

Publication number
US3614955A
US3614955A US9935A US3614955DA US3614955A US 3614955 A US3614955 A US 3614955A US 9935 A US9935 A US 9935A US 3614955D A US3614955D A US 3614955DA US 3614955 A US3614955 A US 3614955A
Authority
US
United States
Prior art keywords
heart
sensing
defibrillator
automatically
capacitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US9935A
Inventor
Mieczyslaw Mirowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Inc
Original Assignee
Medtronic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medtronic Inc filed Critical Medtronic Inc
Application granted granted Critical
Publication of US3614955A publication Critical patent/US3614955A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/021Measuring pressure in heart or blood vessels
    • A61B5/0215Measuring pressure in heart or blood vessels by means inserted into the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00Measuring for diagnostic purposes; Identification of persons
    • A61B5/02Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A61B5/026Measuring blood flow
    • A61B5/0275Measuring blood flow using tracers, e.g. dye dilution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/38Applying electric currents by contact electrodes alternating or intermittent currents for producing shock effects
    • A61N1/39Heart defibrillators
    • A61N1/3956Implantable devices for applying electric shocks to the heart, e.g. for cardioversion

Definitions

  • the heart function is continuously monitored. When the function becomes abnormal, the malfunctioning heart is automatically shocked by a voltage of substantial size. If the heart does not return to its normal functions after a given interval, then it is again shocked. Normal heart activity ensures that the shocking mechanism remains inert.
  • the first step is the detection of those prone to suffering from cardiac malfunctions leading to ventricular tachycardia or ventricular fibrillation.
  • an automatic defibrillator would be an asset to those hospital patients Who have suifered myocardial infarction and who have been discharged from the wellequipped coronary care unit. Under such circumstances, the defibrillator could be implanted temporarily for the remainder of the expected hospital stay; or the defibrillator could be permanently implanted for use both in the hospital and after discharge. And another recognizable class of patients particularly in need of an automatic defibrillator is the class composed of those who have not shown prior histories of myocardial infarction but who show severe symptoms of coronary heart disease, such as ventricular arrhythmias resistant to medical treatment or angina pectoris.
  • the present invention relates to a standby defibrillator, an electronic system which, after detecting one of the above-noted life threatening arrhythmias, automatically defibrillates the heart of the user.
  • the system of the present invention may be installed in patients particularly prone to develop ventricular tachycardia and/or ventricular fibrillation, either on a temporary or a permanent basis.
  • the device of the present invention may be entirely implanted under the skin of the patient, or alternatively, may be carried externally, save for the sensing electrode and one shock-applying electrode.
  • the present invention relates to a device for reliably sensing the differences between a properly functioning heart and one which has suddenly developed ventricular fibrillation, and which then delivers a defibrillating shock to the heart in fibrillation.
  • the device is adapted to continue delivering intermittent shocks to the heart in the event that the heart fails to return to its normal behavior pattern, and has the ability of automatically regaining sensing control over a functional heart thereby ensuring that further shocks are inhibited after successful defibrillation has taken place.
  • the standby defibrillator of the present invention has as its basic element, a capacitor capable of storing electrical energy in an amount suflicient to depolarize the human heart (on the order of 50 joules). Upon discharge of this capacitor, a shock is delivered to the heart through two stimulating electrodes. One of these electrodes is positioned within the right ventricle, thereby forming the distal tip of an intracardiac catheter. This electrode is introduced through a peripheral vein. The second stimulating electrode is positioned either on the surface of the chest, or is sutured under the skin of the anterior chest wall or directly to the ventricular myocardium.
  • the capacitor is associated with a sensing circuit connected to the proximal end of the intracardiac catheter and is adapted to respond to a signal recorded at the dis tal end of the catheter.
  • the signal sensed by the catheter must, of course, be inherently related to some distinctive characteristic of ventricular tachycardia or ventricular fibrillation; and in a specific embodiment of the present invention, the pressure in the right ventricle is sensed. When this pressure falls below a given value, on the order of 10 to 15 mm. Hg, the heart is malfunctioning and, therefore, the capacitor is discharged into the heart.
  • the sensing circuit and the capacitor Between the sensing circuit and the capacitor, means are provided for delaying the repetition of depolarizing discharges for a preset period of time (on the order of 20 to 30 seconds). This delay is essential to give the heart the opportunity to convert spontaneously to a normal cardiac rhythm, and also to ensure that the abnormal heart conditions are, in fact, critical. Only in the absence of a successful conversion is a subsequent shock delivered to the heart.
  • the time delay is brought about with the aid of a sawtooth generator, a relay and the charge time of the storage capacitor.
  • FIG. 1 is a side view of the combination sensing probe and shock-applying probe forming a part of the present invention
  • FIG. 2 illustrates a typical pressure curve for the right ventricle of a normally functioning heart
  • FIG. 3 is a circuit schematic of the electronics comprising the standby defibrillator of the present invention.
  • FIG. 4 is a graph of voltage versus time illustrating the operation of the sawtooth generator forming a part of the present invention.
  • the sensing probe is shown generally at and comprises a main body portion 12 and a pressure sensitive bulb 14. Electrical connections to the bulb 14 are made at junction box 16.
  • One of the shock delivering probes is shown generally at 18 and comprises a main body portion 20, a first ring electrode 22 and a second ring electrode 24. As will be explained below, the electrodes 22 and 24 are short-circuited together during the operation of the device, forming a composite electrode shown at 26.
  • the main body 12 of the sensing probe 10 is in the shape of a fiat ribbon, and the body of the bulb 14 is spherical.
  • the shock delivering probe 18 is substantially cylindrical.
  • the combination sensing probe 10 and shock delivering probe 18 is, during operation, positioned in the right ventricle of the heart. These probes are introduced into the heart through a peripheral vein by means of surgery very similar to that involved in the implantation of a pacemaker probe.
  • the shock delivering electrodes are two in number.
  • the first electrode is the composite electrode 26 and is carried by the shock delivering probe 18.
  • the second electrode is shown at 28 and, in the preferred embodiment of this invention, is a flat plate either placed on the surface of the chest, sutured under the skin of the anterior chest wall or applied directly to the ventricular myocardium.
  • the electrodes 22 and 24 are independent of one another. At this time, conventional pacemaking signals are applied between the electrodes 22 and 24. Since the heart responds favorably to the pacemaking signals only if the probe 18 is properly positioned, this method is suitable for checking the position of the probes 10 and 18. The probe location may, of course, be recognized by other methods such as, for example, fiuoroscopy or pressure recordings. Once it is determined that the probes 10 and 18 are properly located, they are secured in place and the pacemaking electronics are disconnected.
  • the electrodes 22 and 24 are externally short-circuited together, and the electronic circuit associated with the standby defibrillator of the present invention is then connected to the probes 10 and 18 and the electrode 28. If a pacemaking function is also to be carried out, the pacer electronics will remain connected and the step of shorting together the electrodes 22 and 24 will be eliminated.
  • FIG. 2 there is illustrated a right ventricular pressure curve for a normally functioning heart. Pulses 30 and 32 are illustrated but, as is well known, these pulses repeat at the rate of approximately 60 to 70 per minute in a normally functioning heart.
  • FIG. 2 clearly shows that each pulse has a peak and that these peaks rise above a preset pressure indicated by the dotted line 38. This dotted line corresponds to the threshold between a healthy heart and one which is in need of defibrillation.
  • probe 10 which, as will be described immediately below, initiates the defibrillation of the heart.
  • the electronic circuitry of FIG. 3 may conveniently be broken down into several component parts.
  • the first part is a pressure transducer shown at 40, this pressure transducer being directly associated with the pressure sensing probe 10 shown in FIG. 1.
  • the next state of the electronics is an amplifier shown at 42 and adapted to amplify the signals received from the pressure transducer 40.
  • the amplified signal from the amplifier 42 is then passed to a sawtooth generator shown at 44, which generator, in turn feeds its output signal to the base of a transistor associated with the relay stage shown at 46.
  • the relay 46 is normally in its open state condition but, when it is closed, a DC signal is impressed upon a DC/DC converter stage 48.
  • the DC/DC converter 48 boosts the input voltage from approximately 15 volts to approximately 2,500 volts.
  • the 2,500 volt DC signal from the converter 48 is then fed to a storage capacitor 70 which is associated with a firing circuit, the entire combination shown at 50.
  • the firing circuit 50 allows the capacitor 70 to discharge, the 2,500-volt signal is applied to the electrodes 26 and 28 illustrated in FIG. 1. Therefore, when the pressure sensing probe It) recognizes a malfunction in the heart, the capacitor, after a predetermined time delay, shocks the heart with approximately 2,500 volts. This voltage corresponds to approximately 50 joules of power, enough power to cause most hearts to defibrillate.
  • the pressure transducer 40 takes the form of a resistive bridge, one resistor of which is defined by the pressure sensor 14 on the tip of the probe 10. The remaining legs in the bridge are defined by resistors housed in the junction box 16 shown in FIG. 1.
  • the pressure trans ducer 40 is arranged so that the pressure sensed by element 14 is converted to an electrical signal, the amplitude of which is directly proportional to the pressure sensed by the element 14.
  • the output from the pressure transducer 40 is fed to a conventional amplifier 42 which amplifies the received pulses and which then feeds these amplified pulses to the sawtooth generator 44.
  • the trimming potentiometer 52 seems to balance the inputs to the associated amplifier.
  • the sawtooth generator 44 if unafi'ected by the external environment, will have an output curve such as that shown at 54 in FIG. 4. However, if a signal is fed to the sawtooth generator, via lead 56, and if the signal is at least of a predeterminded amplitude, then the output voltage of the generator will immediately drop to zero and then again begin to climb. Therefore, if the sawtooth generator receives repetitious pulses of at least the predetermined voltage, then its output will be similar to that of curve 58 shown in FIG. 4.
  • the amplified signal corresponding to a pulse in the right ventricular pressure will cause the output of the sawtooth generator 44 to drop to zero.
  • the threshold signal reaching the generator via lead 56 can be adjusted by adjusting the amplification factor of the signal amplifier 42. This threshold is adjusted so that the generator 44 activates the relay 64 only after approximately six seconds of heart malfunction. If, then, the ventricular pressure falls lower than that value indicated by the dotted line 38, and so remains for the preset time interval, the amplified voltage reaching the generator 44, via lead 56, will be insuflicient to cause the generator output to drop to zero. Rather, the generator output will follow the curve shown at 54 in FIG. 4. Trimming potentiometer 60 is provided to balance the inputs to the associated amplifier.
  • the output from the sawtooth generator 44 is fed to the relay circuit 46.
  • the relay contacts shown generally at 64 are initially set in the open-circuit condition, thereby isolating the 15-volt source from the D-C/DC converter 48. Further, the relay 64 is set to close only after the current passing through coil 66 reaches a predetermined value. With reference to FIG. 4, the voltage output of the sawtooth generator 44 must be at the level 68 before the current in the coil 66 is sufficient to switch the relay 64 into its closed-circuit state.
  • the operation of the firing circuit 50 is as follows: the 2,5 00-volt signal from the converter 48 is fed to the capacitor 70.
  • the transistor 72 becomes conductive, due to the now-conducting neon tube 74.
  • the resistor chains and the tube 74 are interconnected in such a manner that when the voltage across the capacitor 70 reaches the full 2,500 volts, then the tube 74 becomes conductive.
  • the tube 74 conducts, so too does transistor 72 and, therefore, SCR 76.
  • the full 2,500 volts pass through electrodes 26 and 28 thus shocking the heart with a voltage sufiicient to cause defibrillation.
  • a time period elapse between the detection of a heart malfunction and the delivery of the defibrillating shock to the heart.
  • approximately six seconds of delay occur between the first detection of a malfunction and the closing of the relay 64.
  • the capacitor employed in the preferred embodiment charges in approximately fifteen seconds. Therefore, approximately twenty-one seconds elapse between the initial sensing of heart malfunction and the discharge of the capacitor into the heart.
  • the twenty-one seconds may be enlarged or contracted as desired. And, as mentioned above, if at any time during the delay period the heart returns to normal, then the delay period automatically begins again.
  • a device for automatically cardioverting a malfunctioning heart comprising: means for continually sensing the function of a heart; means associated with said sensing means for discriminating between normal heart function and abnormal heart function; means for storing electrical energy for cardioverting a malfunctioning heart; electrode means associated with said storage means for connecting the storage means directly to the heart; at least one of said electrode means adapted to be positioned within the heart; and means for automatically switching said storage means into a discharge state in response to an abnormal condition indication from said discriminating means whereby the stored energy is applied directly to the heart through said electrode means.
  • the method of automatically sensing and cardioverting a malfunctioning heart comprising the steps of: continually sensing the function of the heart; discriminating between normal heart function and abnormal heart function; automatically starting a cycle for shocking the heart, in response to the sensing of abnormal 7 heart function, shocking the heart to cause cardioversion; and positively inhibiting the heart shocking cycle under conditions of normal heart function.
  • a device for automatically cardioverting a malfunctioning heart comprising: means for continually sensing the function of a heart; means associated with said sensing means for discriminating between normal heart function and abnormal heart function; means for storing electrical energy for cardioverting a malfunctioning heart; electrode means associated with said storage means for connecting the storage means directly to the heart; means for automatically switching said storage means into a discharge state whereby the stored energy is applied directly to the heart through said electrode means; delay means for ensuring that a time delay exists between the sensing of the initial heart malfunction and the discharge of said storage means into the heart; and means UNITED STATES PATENTS 3,135,264 6/1964 Tischler et al 1284l9 D 3,236,239 2/1966 Berkovits 128419 D 3,358,690 12/1967 Cohen l28419 D 3,481,341 12/1969 Siedband 1284l9 D WILLIAM E. KAMM, Primary Examiner US. Cl. X.R. l28-2.05 P, 2.06 A

Abstract

A METHOD AND MEANS FOR AUTOMATICALLY DEFIBRILLATING A MALFUNCTIONING HEART. WITH THE PRESENT INVENTION, THE HEART FUNCTION IS CONTINUOUSLY MONITORED. WHEN THE FUNCTION BECOMES ABNORMAL, THE MALFUNCTIONING HEART IS AUTOMATICALLY SHOCKED BY A VOLTAGE OF SUBSTANTIAL SIZE. IF THE HEART DOES NOT RETURN TO ITS NORMAL FUNCTIONS AFTER A GIVEN INTERVAL, THEN IT IS AGAIN SHOCKED. NORMAL HEART ACTIVITY ENSURES THAT THE SHOCKING MACHANISM REMAINS INERT.

Description

Oct. 26; 1971 M WROWSK. ETAL 3,614,955
STANDBY DEFIBRILLATOR AND METHOD OF OPERATION Filed Feb. 9, 1970 2 Sheets-Shoot 1 All m2;
HSVJJOA INVENTOR MIECZYSLAW MIROWSKI BY 5 0/ I a J 7 ATTORNEYS Oct. 26, M, M|ROWSK| ETAL 3,614,955
STANDBY DEFIBRILLATOR AND METHOD OF OPERATION Filed Feb. 9. 1970 2 Sheets-Shoot I! R I K I lllll IIWWV. llll m m WMQOEFOMJU OF P l m M \bh w A L S Y- Z c n E M BY /z i Z ATTORNEYS nited States 3,fil4,955 Patented Oct. 26, 1971 3,614,955 STANDBY DEFIBRILLATOR AND METHOD OF OPERATEON Mieczyslaw Mirowski, Baltimore, Md., assignor to Medtronic, Inc., Minneapolis, Minn. Filed Feb. 9, 1970, Ser. No. 9335 Int. Cl. A61n 1/34 U.S. Cl. 128-419 D 6 Claims ABSTRACT OF THE DISCLOSURE A method and means for automatically defibrillating a malfunctioning heart. With the present invention, the heart function is continuously monitored. When the function becomes abnormal, the malfunctioning heart is automatically shocked by a voltage of substantial size. If the heart does not return to its normal functions after a given interval, then it is again shocked. Normal heart activity ensures that the shocking mechanism remains inert.
BACKGROUND OF THE INVENTION During the past several decades, coronary heart disease has come to occupy the first position among the causes of death in the developed areas of the world. In the United States, for example, this disease is responsible for over one-half million deaths yearly. And of this number, more than half occur suddenly, outside the hospital, and therefore before the patient is able to obtain the necessary medical assistance. Although the precise cause of sudden death in coronary heart disease has not yet been entirely clarified, the available evidence permits the medical field to ascribe death in the majority of these cases to grave disturbances in cardiac electrical activity resulting in ventricular fibrillation.
Recent experience has clearly demonstrated that ventricular fibrillation and its frequent precursor, ventricular tachycardia, are reversible phenomena when prompt defibrillation of the heart is instituted. Under such circumstances, cardiac function can frequently be restored to normal without the patient suffering from residual disability. Unfortunately, however, the state of the art makes defibrillation very much dependent upon a highly specialized medical environment, thus limiting such treatment to elaborately equipped modern hospitals.
At the present, therefore, a great need exists for a defibrillator which could be carried by those who are prone to having one of the many life threatening arrhythmias generally discussed above. Thus, in some patients having coronary heart disease, a fatal outcome from ventricular tachycardia or ventricular fibrillation could be avoided, even in the absence of immediate medical assistance. The first step, of course, is the detection of those prone to suffering from cardiac malfunctions leading to ventricular tachycardia or ventricular fibrillation.
While it is not possible to predict with unerring exactness which patient suffering from coronary heart disease will be the victim of sudden death, several high risk groups of patients can be recognized. For example, patients who have experienced myocardial infarction, even though they may be surviving in good health, run a substantial risk of dying suddenly, a risk several times greater than that associated with the general population. Further, if patients with myocardial infarction have a history of serious ventricular arrhythmias and/or of cardiac arrest, or if evidence of persistent myocardial irritability is present, it may be logically assumed that the risk of sudden death is increased substantially. Patients like those described above would greatly benefit if an automatic, standby or demand defibrillator were available.
Also, such an automatic defibrillator would be an asset to those hospital patients Who have suifered myocardial infarction and who have been discharged from the wellequipped coronary care unit. Under such circumstances, the defibrillator could be implanted temporarily for the remainder of the expected hospital stay; or the defibrillator could be permanently implanted for use both in the hospital and after discharge. And another recognizable class of patients particularly in need of an automatic defibrillator is the class composed of those who have not shown prior histories of myocardial infarction but who show severe symptoms of coronary heart disease, such as ventricular arrhythmias resistant to medical treatment or angina pectoris.
From the brief discussion above, there should be little doubt that the possible applications for an automatic defibrillator are numerous. And, as previously noted, there is at present no known device which meets the need. It is toward filling this gap in medical instrumentation that the present invention is directed.
SUMMARY OF THE INVENTION The present invention relates to a standby defibrillator, an electronic system which, after detecting one of the above-noted life threatening arrhythmias, automatically defibrillates the heart of the user. The system of the present invention may be installed in patients particularly prone to develop ventricular tachycardia and/or ventricular fibrillation, either on a temporary or a permanent basis. And, because of its small size, the device of the present invention may be entirely implanted under the skin of the patient, or alternatively, may be carried externally, save for the sensing electrode and one shock-applying electrode.
More particularly, the present invention relates to a device for reliably sensing the differences between a properly functioning heart and one which has suddenly developed ventricular fibrillation, and which then delivers a defibrillating shock to the heart in fibrillation. The device is adapted to continue delivering intermittent shocks to the heart in the event that the heart fails to return to its normal behavior pattern, and has the ability of automatically regaining sensing control over a functional heart thereby ensuring that further shocks are inhibited after successful defibrillation has taken place.
The standby defibrillator of the present invention has as its basic element, a capacitor capable of storing electrical energy in an amount suflicient to depolarize the human heart (on the order of 50 joules). Upon discharge of this capacitor, a shock is delivered to the heart through two stimulating electrodes. One of these electrodes is positioned within the right ventricle, thereby forming the distal tip of an intracardiac catheter. This electrode is introduced through a peripheral vein. The second stimulating electrode is positioned either on the surface of the chest, or is sutured under the skin of the anterior chest wall or directly to the ventricular myocardium.
The capacitor is associated with a sensing circuit connected to the proximal end of the intracardiac catheter and is adapted to respond to a signal recorded at the dis tal end of the catheter. The signal sensed by the catheter must, of course, be inherently related to some distinctive characteristic of ventricular tachycardia or ventricular fibrillation; and in a specific embodiment of the present invention, the pressure in the right ventricle is sensed. When this pressure falls below a given value, on the order of 10 to 15 mm. Hg, the heart is malfunctioning and, therefore, the capacitor is discharged into the heart.
Between the sensing circuit and the capacitor, means are provided for delaying the repetition of depolarizing discharges for a preset period of time (on the order of 20 to 30 seconds). This delay is essential to give the heart the opportunity to convert spontaneously to a normal cardiac rhythm, and also to ensure that the abnormal heart conditions are, in fact, critical. Only in the absence of a successful conversion is a subsequent shock delivered to the heart. In a particular embodiment of the present invention, the time delay is brought about with the aid of a sawtooth generator, a relay and the charge time of the storage capacitor.
Accordingly, it is the main object of the present invention to provide a compact and automatic standby d..- fibrillator which lies dormant during normal heart activity but which applies a shock to the heart when the heart functions become abnormal.
It is another object of the present invention to provide a standby defibrillator which reliably senses the difference between a normally functioning heart and one that has suddenly developed abnormal function, and which then automatically delivers a defibrillating shock to the heart.
It is a further object of the present invention to provide a standby defibrillator which is capable of delivering multiple shocks in the event that the heart is not successfully cardioverted by the initial shock.
It is yet a further object of the invention to provide a standby defibrillator which automatically regains sensing control over a functioning heart, thereby inhibiting further shocks after successful defibrillation.
It is still another object of the invention to provide a device employing a heart-implanted catheter which may sense both for defibrillation and for pacing the heart if required.
It is still another object of the present invention to provide a standby defibrillator which is extremely compact and which is therefore totally implantable in the body of a patient.
It is still another object of the invention to provide a method of operating a standby defibrillator.
These and other objects of the invention, as well as many of the attendant advantages thereof, will become more readily apparent when reference is made to the following description taken in conjunction with the accompanying drawings.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a side view of the combination sensing probe and shock-applying probe forming a part of the present invention;
FIG. 2 illustrates a typical pressure curve for the right ventricle of a normally functioning heart;
FIG. 3 is a circuit schematic of the electronics comprising the standby defibrillator of the present invention; and
FIG. 4 is a graph of voltage versus time illustrating the operation of the sawtooth generator forming a part of the present invention.
DETAILED DESCRIPTION OF THE INVENTION With reference first to FIG. 1, the sensing and shock delivering probes will be described. The sensing probe is shown generally at and comprises a main body portion 12 and a pressure sensitive bulb 14. Electrical connections to the bulb 14 are made at junction box 16. One of the shock delivering probes is shown generally at 18 and comprises a main body portion 20, a first ring electrode 22 and a second ring electrode 24. As will be explained below, the electrodes 22 and 24 are short-circuited together during the operation of the device, forming a composite electrode shown at 26. The main body 12 of the sensing probe 10 is in the shape of a fiat ribbon, and the body of the bulb 14 is spherical. The shock delivering probe 18 is substantially cylindrical.
As noted previously, the combination sensing probe 10 and shock delivering probe 18 is, during operation, positioned in the right ventricle of the heart. These probes are introduced into the heart through a peripheral vein by means of surgery very similar to that involved in the implantation of a pacemaker probe.
The shock delivering electrodes are two in number. The first electrode is the composite electrode 26 and is carried by the shock delivering probe 18. The second electrode is shown at 28 and, in the preferred embodiment of this invention, is a flat plate either placed on the surface of the chest, sutured under the skin of the anterior chest wall or applied directly to the ventricular myocardium.
When the sensing probe 10 and the shock delivering probe 18 are inserted into the heart, the electrodes 22 and 24 are independent of one another. At this time, conventional pacemaking signals are applied between the electrodes 22 and 24. Since the heart responds favorably to the pacemaking signals only if the probe 18 is properly positioned, this method is suitable for checking the position of the probes 10 and 18. The probe location may, of course, be recognized by other methods such as, for example, fiuoroscopy or pressure recordings. Once it is determined that the probes 10 and 18 are properly located, they are secured in place and the pacemaking electronics are disconnected. Then, the electrodes 22 and 24 are externally short-circuited together, and the electronic circuit associated with the standby defibrillator of the present invention is then connected to the probes 10 and 18 and the electrode 28. If a pacemaking function is also to be carried out, the pacer electronics will remain connected and the step of shorting together the electrodes 22 and 24 will be eliminated.
With reference now to FIG. 2, there is illustrated a right ventricular pressure curve for a normally functioning heart. Pulses 30 and 32 are illustrated but, as is well known, these pulses repeat at the rate of approximately 60 to 70 per minute in a normally functioning heart. FIG. 2 clearly shows that each pulse has a peak and that these peaks rise above a preset pressure indicated by the dotted line 38. This dotted line corresponds to the threshold between a healthy heart and one which is in need of defibrillation. When the height of the peaks 34 and 36 fall below the pressure indicated by line 38, the malfunction is sensed by probe 10 which, as will be described immediately below, initiates the defibrillation of the heart.
With reference then to FIG. 3, the electronics associated with the standby defibrillator will be described. The electronic circuitry of FIG. 3 may conveniently be broken down into several component parts. The first part is a pressure transducer shown at 40, this pressure transducer being directly associated with the pressure sensing probe 10 shown in FIG. 1. The next state of the electronics is an amplifier shown at 42 and adapted to amplify the signals received from the pressure transducer 40. The amplified signal from the amplifier 42 is then passed to a sawtooth generator shown at 44, which generator, in turn feeds its output signal to the base of a transistor associated with the relay stage shown at 46. The relay 46 is normally in its open state condition but, when it is closed, a DC signal is impressed upon a DC/DC converter stage 48. The DC/DC converter 48 boosts the input voltage from approximately 15 volts to approximately 2,500 volts. The 2,500 volt DC signal from the converter 48 is then fed to a storage capacitor 70 which is associated with a firing circuit, the entire combination shown at 50. When the firing circuit 50 allows the capacitor 70 to discharge, the 2,500-volt signal is applied to the electrodes 26 and 28 illustrated in FIG. 1. Therefore, when the pressure sensing probe It) recognizes a malfunction in the heart, the capacitor, after a predetermined time delay, shocks the heart with approximately 2,500 volts. This voltage corresponds to approximately 50 joules of power, enough power to cause most hearts to defibrillate.
Still referring to FIG. 3, but in greater detail, the circuitry associated with the present invention functions as follows. The pressure transducer 40 takes the form of a resistive bridge, one resistor of which is defined by the pressure sensor 14 on the tip of the probe 10. The remaining legs in the bridge are defined by resistors housed in the junction box 16 shown in FIG. 1. The pressure trans ducer 40 is arranged so that the pressure sensed by element 14 is converted to an electrical signal, the amplitude of which is directly proportional to the pressure sensed by the element 14.
The output from the pressure transducer 40 is fed to a conventional amplifier 42 which amplifies the received pulses and which then feeds these amplified pulses to the sawtooth generator 44. The trimming potentiometer 52 seems to balance the inputs to the associated amplifier.
With reference now to FIGS. 2 through 4, the operation of the sawtooth generator 44 will be described. The sawtooth generator 44, if unafi'ected by the external environment, will have an output curve such as that shown at 54 in FIG. 4. However, if a signal is fed to the sawtooth generator, via lead 56, and if the signal is at least of a predeterminded amplitude, then the output voltage of the generator will immediately drop to zero and then again begin to climb. Therefore, if the sawtooth generator receives repetitious pulses of at least the predetermined voltage, then its output will be similar to that of curve 58 shown in FIG. 4.
If the heart functions sensed by the pressure transducer 40 are normal, following the curve shown in FIG. 2, then the amplified signal corresponding to a pulse in the right ventricular pressure will cause the output of the sawtooth generator 44 to drop to zero. The threshold signal reaching the generator via lead 56, can be adjusted by adjusting the amplification factor of the signal amplifier 42. This threshold is adjusted so that the generator 44 activates the relay 64 only after approximately six seconds of heart malfunction. If, then, the ventricular pressure falls lower than that value indicated by the dotted line 38, and so remains for the preset time interval, the amplified voltage reaching the generator 44, via lead 56, will be insuflicient to cause the generator output to drop to zero. Rather, the generator output will follow the curve shown at 54 in FIG. 4. Trimming potentiometer 60 is provided to balance the inputs to the associated amplifier.
The output from the sawtooth generator 44 is fed to the relay circuit 46. The relay contacts shown generally at 64 are initially set in the open-circuit condition, thereby isolating the 15-volt source from the D-C/DC converter 48. Further, the relay 64 is set to close only after the current passing through coil 66 reaches a predetermined value. With reference to FIG. 4, the voltage output of the sawtooth generator 44 must be at the level 68 before the current in the coil 66 is sufficient to switch the relay 64 into its closed-circuit state.
When the relay 64 closes, then the l5-volt source is connected directly to the DC/ DC converter 48. From FIGS. 2 through 4, it should be evident that approximately six seconds must elapse, with the heart continuously malfunctioning, before the relay 64 switches from its opencircuit mode to its closed-circuit mode. This will be apparent when one realizes that each tooth of the curve 58 corresponds to one peak of the right ventricular pressure curve and, as noted above, the peaks of the pressure curve repeat at approximately 60 to 70 per minute. Therefore, the heart pressure must be below the threshold level for approximately six seconds before input voltage is fed to the DC/ DC converter 48. If the heart returns to its normal function at any time during that Six seconds, then the sawtooth generator output response would drop to zero and the six second cycle would begin again.
With the relay 64 closed and a 15-volt DC signal being impressed upon the converter 48, an output of 2,500 volts appears at the output terminals of the converter 48. This voltage is fed directly to storage capacitor 70. Simultaneously, the 2,500-volt signal is fed to a resistive chain and finally to the base of transistor 72 via a neon tube 74. A silicon controlled rectifier (SCR) is triggered on when transistor 72 becomes conductive.
The operation of the firing circuit 50 is as follows: the 2,5 00-volt signal from the converter 48 is fed to the capacitor 70. When the capacitor 70 is fully charged, the transistor 72 becomes conductive, due to the now-conducting neon tube 74. The resistor chains and the tube 74 are interconnected in such a manner that when the voltage across the capacitor 70 reaches the full 2,500 volts, then the tube 74 becomes conductive. When the tube 74 conducts, so too does transistor 72 and, therefore, SCR 76. Then, the full 2,500 volts pass through electrodes 26 and 28 thus shocking the heart with a voltage sufiicient to cause defibrillation.
As above noted, it is important that a time period elapse between the detection of a heart malfunction and the delivery of the defibrillating shock to the heart. As also noted above, approximately six seconds of delay occur between the first detection of a malfunction and the closing of the relay 64. There is an additional delay, on the order of fifteen seconds, which is brought about by the charge time of the capacitor 70. That is, when the relay 64 closes, six seconds after the initial malfunction, the capacitor first begins to charge. The capacitor employed in the preferred embodiment charges in approximately fifteen seconds. Therefore, approximately twenty-one seconds elapse between the initial sensing of heart malfunction and the discharge of the capacitor into the heart. Naturally by varying the rise time of the sawtooth generator and the charge time of the capacitor, the twenty-one seconds may be enlarged or contracted as desired. And, as mentioned above, if at any time during the delay period the heart returns to normal, then the delay period automatically begins again.
Above, a specific embodiment of the present invention has been described. It should be understood, however, that this description is given for illustrative purposes only and that many alterations and modifications may be practiced without departing from the spirit and scope of the invention. Just as a few examples, it should be understood that while in the specific embodiment of the present invention, the pressure in the right ventricle is sensed as an indication of heart malfunction, other sensing arrangements may be practiced. Further, a single SCR is used as a triggering device. It is possible to substitute this device for a plurality of SCR units or, alternatively, with a vacuum relay. Still further, while the above description shows a single storage capacitor, a series of capacitors could be employed. It is, therefore, the intent that the present invention not be limited to the above but be limited only as defined in the appended claims.
What is claimed is:
1. A device for automatically cardioverting a malfunctioning heart, the device comprising: means for continually sensing the function of a heart; means associated with said sensing means for discriminating between normal heart function and abnormal heart function; means for storing electrical energy for cardioverting a malfunctioning heart; electrode means associated with said storage means for connecting the storage means directly to the heart; at least one of said electrode means adapted to be positioned within the heart; and means for automatically switching said storage means into a discharge state in response to an abnormal condition indication from said discriminating means whereby the stored energy is applied directly to the heart through said electrode means.
2. The device as set forth in claim 1, and further comprising: delay means for ensuring that a time delay exists between the sensing of the initial heart malfunction and the discharge of said storage means into the heart.
3. The device as set forth in claim 1, and further comprising: means for inhibiting the discharge of said storage means under conditions of normal heart activity.
4. The method of automatically sensing and cardioverting a malfunctioning heart, the method comprising the steps of: continually sensing the function of the heart; discriminating between normal heart function and abnormal heart function; automatically starting a cycle for shocking the heart, in response to the sensing of abnormal 7 heart function, shocking the heart to cause cardioversion; and positively inhibiting the heart shocking cycle under conditions of normal heart function.
5. A device for automatically cardioverting a malfunctioning heart, the device comprising: means for continually sensing the function of a heart; means associated with said sensing means for discriminating between normal heart function and abnormal heart function; means for storing electrical energy for cardioverting a malfunctioning heart; electrode means associated with said storage means for connecting the storage means directly to the heart; means for automatically switching said storage means into a discharge state whereby the stored energy is applied directly to the heart through said electrode means; delay means for ensuring that a time delay exists between the sensing of the initial heart malfunction and the discharge of said storage means into the heart; and means UNITED STATES PATENTS 3,135,264 6/1964 Tischler et al 1284l9 D 3,236,239 2/1966 Berkovits 128419 D 3,358,690 12/1967 Cohen l28419 D 3,481,341 12/1969 Siedband 1284l9 D WILLIAM E. KAMM, Primary Examiner US. Cl. X.R. l28-2.05 P, 2.06 A
US9935A 1970-02-09 1970-02-09 Standby defibrillator and method of operation Expired - Lifetime US3614955A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US993570A 1970-02-09 1970-02-09

Publications (1)

Publication Number Publication Date
US3614955A true US3614955A (en) 1971-10-26

Family

ID=21740585

Family Applications (1)

Application Number Title Priority Date Filing Date
US9935A Expired - Lifetime US3614955A (en) 1970-02-09 1970-02-09 Standby defibrillator and method of operation

Country Status (2)

Country Link
US (1) US3614955A (en)
CA (1) CA981338A (en)

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3738370A (en) * 1971-01-18 1973-06-12 B Charms Method of defibrillating a malfunctioning heart by means of electrodes located within the atrium
US3815611A (en) * 1971-11-26 1974-06-11 Medtronic Inc Muscle stimulation and/or contraction detection device
US4026302A (en) * 1975-04-30 1977-05-31 Joseph Grayzel Method of implanting a permanent pacemaker bipolar lead apparatus and an implantable permanent pacemaker bipolar lead apparatus
US4289134A (en) * 1979-07-23 1981-09-15 Electro-Catheter Corporation Tripolar catheter apparatus
US4440172A (en) * 1980-10-02 1984-04-03 Mieczyslaw Mirowski Apparatus for combining pacing and cardioverting functions in a single implanted device
US4475551A (en) * 1980-08-05 1984-10-09 Mieczyslaw Mirowski Arrhythmia detection and defibrillation system and method
US4574807A (en) * 1984-03-02 1986-03-11 Carl Hewson Method and apparatus for pacing the heart employing external and internal electrodes
US4683890A (en) * 1985-12-23 1987-08-04 Brunswick Manufacturing Co., Inc. Method and apparatus for controlled breathing employing internal and external electrodes
US4693253A (en) * 1981-03-23 1987-09-15 Medtronic, Inc. Automatic implantable defibrillator and pacer
US4708145A (en) * 1982-06-01 1987-11-24 Medtronic, Inc. Sequential-pulse, multiple pathway defibrillation method
US4768512A (en) * 1986-05-13 1988-09-06 Mieczyslaw Mirowski Cardioverting system and method with high-frequency pulse delivery
US4825871A (en) * 1984-03-27 1989-05-02 Societe Anonyme Dite: Atesys Defibrillating or cardioverting electric shock system including electrodes
US4834100A (en) * 1986-05-12 1989-05-30 Charms Bernard L Apparatus and method of defibrillation
EP0326290A1 (en) * 1988-01-19 1989-08-02 Telectronics N.V. Method and apparatus for applying asymmetric biphasic truncated exponential countershocks
DE3914662A1 (en) * 1989-05-03 1990-11-08 Alt Eckhard DEVICE FOR TRANSMITTING ELECTRICAL SIGNALS BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND ELECTRICALLY EXPENSIBLE HUMAN TISSUE
US5083562A (en) * 1988-01-19 1992-01-28 Telectronics Pacing Systems, Inc. Method and apparatus for applying asymmetric biphasic truncated exponential countershocks
US5083563A (en) * 1990-02-16 1992-01-28 Telectronics Pacing Systems, Inc. Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker
US5105810A (en) * 1990-07-24 1992-04-21 Telectronics Pacing Systems, Inc. Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker with means for minimizing bradycardia support pacing voltages
US5156148A (en) * 1987-10-06 1992-10-20 Leonard Bloom System for treating a malfunctioning heart
US5184614A (en) * 1990-10-19 1993-02-09 Telectronics Pacing Systems, Inc. Implantable haemodynamically responsive cardioverting/defibrillating pacemaker
US5282837A (en) * 1991-04-12 1994-02-01 Incontrol, Inc. Atrial defibrillator and method
US5342403A (en) * 1993-04-09 1994-08-30 Hewlett-Packard Corporation Integrated defibrillator/monitor architecture with defibrillator-only fail-safe mode of operation
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5391187A (en) * 1994-02-22 1995-02-21 Zmd Corporation Semiautomatic defibrillator with heart rate alarm driven by shock advisory algorithm
US5409009A (en) * 1994-03-18 1995-04-25 Medtronic, Inc. Methods for measurement of arterial blood flow
US5433729A (en) * 1991-04-12 1995-07-18 Incontrol, Inc. Atrial defibrillator, lead systems, and method
US5507778A (en) * 1994-02-22 1996-04-16 Zmd Corporation Semiautomatic defibrillator with synchronized shock delivery
US5547467A (en) * 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
US5738105A (en) * 1995-10-24 1998-04-14 Angeion Corporation Method and apparatus for sensing R-waves using both near field and far field sensing simultaneously
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5911223A (en) * 1996-08-09 1999-06-15 Massachusetts Institute Of Technology Introduction of modifying agents into skin by electroporation
US5913887A (en) * 1996-03-01 1999-06-22 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter including three coil electrodes
US5916238A (en) * 1990-04-25 1999-06-29 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US5983131A (en) * 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US6085119A (en) * 1998-07-22 2000-07-04 Cardiac Pacemakers, Inc. Single pass endocardial lead for multi-site atrial pacing
US6085115A (en) * 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US6152954A (en) * 1998-07-22 2000-11-28 Cardiac Pacemakers, Inc. Single pass lead having retractable, actively attached electrode for pacing and sensing
US6212434B1 (en) 1998-07-22 2001-04-03 Cardiac Pacemakers, Inc. Single pass lead system
US6321122B1 (en) 1998-07-22 2001-11-20 Cardiac Pacemakers, Inc. Single pass defibrillation/pacing lead with passively attached electrode for pacing and sensing
US6463334B1 (en) 1998-11-02 2002-10-08 Cardiac Pacemakers, Inc. Extendable and retractable lead
US6501990B1 (en) 1999-12-23 2002-12-31 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US6501994B1 (en) 1997-12-24 2002-12-31 Cardiac Pacemakers, Inc. High impedance electrode tip
US20030176933A1 (en) * 2000-01-21 2003-09-18 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US20050131469A1 (en) * 2003-12-16 2005-06-16 Leonard Bloom Hemodynamic optimization system for biventricular implants
US20070071685A1 (en) * 2003-12-22 2007-03-29 Bracco Research S.A. Gas-filled microvesicle assembly for contrast imaging
US7245973B2 (en) 2003-12-23 2007-07-17 Cardiac Pacemakers, Inc. His bundle mapping, pacing, and injection lead
EP2075014A2 (en) 2002-05-24 2009-07-01 Angiotech International Ag Compositions and methods for coating medical implants
US7658196B2 (en) 2005-02-24 2010-02-09 Ethicon Endo-Surgery, Inc. System and method for determining implanted device orientation
US7775215B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. System and method for determining implanted device positioning and obtaining pressure data
US7775966B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. Non-invasive pressure measurement in a fluid adjustable restrictive device
US7844342B2 (en) 2008-02-07 2010-11-30 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using light
US20110009641A1 (en) * 2005-06-15 2011-01-13 Anderson Daniel G Amine-containing lipids and uses thereof
US7927270B2 (en) 2005-02-24 2011-04-19 Ethicon Endo-Surgery, Inc. External mechanical pressure sensor for gastric band pressure measurements
US8016744B2 (en) 2005-02-24 2011-09-13 Ethicon Endo-Surgery, Inc. External pressure-based gastric band adjustment system and method
US8016745B2 (en) 2005-02-24 2011-09-13 Ethicon Endo-Surgery, Inc. Monitoring of a food intake restriction device
US8034065B2 (en) 2008-02-26 2011-10-11 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8057492B2 (en) 2008-02-12 2011-11-15 Ethicon Endo-Surgery, Inc. Automatically adjusting band system with MEMS pump
US8066629B2 (en) 2005-02-24 2011-11-29 Ethicon Endo-Surgery, Inc. Apparatus for adjustment and sensing of gastric band pressure
US8100870B2 (en) 2007-12-14 2012-01-24 Ethicon Endo-Surgery, Inc. Adjustable height gastric restriction devices and methods
US8114345B2 (en) 2008-02-08 2012-02-14 Ethicon Endo-Surgery, Inc. System and method of sterilizing an implantable medical device
US8142452B2 (en) 2007-12-27 2012-03-27 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8152710B2 (en) 2006-04-06 2012-04-10 Ethicon Endo-Surgery, Inc. Physiological parameter analysis for an implantable restriction device and a data logger
US8187162B2 (en) 2008-03-06 2012-05-29 Ethicon Endo-Surgery, Inc. Reorientation port
US8187163B2 (en) 2007-12-10 2012-05-29 Ethicon Endo-Surgery, Inc. Methods for implanting a gastric restriction device
US8192350B2 (en) 2008-01-28 2012-06-05 Ethicon Endo-Surgery, Inc. Methods and devices for measuring impedance in a gastric restriction system
US8221439B2 (en) 2008-02-07 2012-07-17 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using kinetic motion
US8233995B2 (en) 2008-03-06 2012-07-31 Ethicon Endo-Surgery, Inc. System and method of aligning an implantable antenna
US8285376B2 (en) 2004-12-20 2012-10-09 Cardiac Pacemakers, Inc. Ventricular pacing
US8290586B2 (en) 2004-12-20 2012-10-16 Cardiac Pacemakers, Inc. Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device
US8326423B2 (en) 2004-12-20 2012-12-04 Cardiac Pacemakers, Inc. Devices and methods for steering electrical stimulation in cardiac rhythm management
US8337389B2 (en) 2008-01-28 2012-12-25 Ethicon Endo-Surgery, Inc. Methods and devices for diagnosing performance of a gastric restriction system
US8377079B2 (en) 2007-12-27 2013-02-19 Ethicon Endo-Surgery, Inc. Constant force mechanisms for regulating restriction devices
US8423139B2 (en) 2004-12-20 2013-04-16 Cardiac Pacemakers, Inc. Methods, devices and systems for cardiac rhythm management using an electrode arrangement
US8538521B2 (en) 2004-12-20 2013-09-17 Cardiac Pacemakers, Inc. Systems, devices and methods for monitoring efficiency of pacing
US8543203B2 (en) 2004-12-20 2013-09-24 Cardiac Pacemakers, Inc. Endocardial pacing devices and methods useful for resynchronization and defibrillation
US8565880B2 (en) 2010-04-27 2013-10-22 Cardiac Pacemakers, Inc. His-bundle capture verification and monitoring
US8591395B2 (en) 2008-01-28 2013-11-26 Ethicon Endo-Surgery, Inc. Gastric restriction device data handling devices and methods
US8591532B2 (en) 2008-02-12 2013-11-26 Ethicon Endo-Sugery, Inc. Automatically adjusting band system
US8688234B2 (en) 2008-12-19 2014-04-01 Cardiac Pacemakers, Inc. Devices, methods, and systems including cardiac pacing
US8870742B2 (en) 2006-04-06 2014-10-28 Ethicon Endo-Surgery, Inc. GUI for an implantable restriction device and a data logger
US8880169B2 (en) 2004-12-20 2014-11-04 Cardiac Pacemakers, Inc. Endocardial pacing relating to conduction abnormalities
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11951180B2 (en) 2023-04-03 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery

Cited By (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3738370A (en) * 1971-01-18 1973-06-12 B Charms Method of defibrillating a malfunctioning heart by means of electrodes located within the atrium
US3815611A (en) * 1971-11-26 1974-06-11 Medtronic Inc Muscle stimulation and/or contraction detection device
US4026302A (en) * 1975-04-30 1977-05-31 Joseph Grayzel Method of implanting a permanent pacemaker bipolar lead apparatus and an implantable permanent pacemaker bipolar lead apparatus
US4289134A (en) * 1979-07-23 1981-09-15 Electro-Catheter Corporation Tripolar catheter apparatus
US4475551A (en) * 1980-08-05 1984-10-09 Mieczyslaw Mirowski Arrhythmia detection and defibrillation system and method
US4440172A (en) * 1980-10-02 1984-04-03 Mieczyslaw Mirowski Apparatus for combining pacing and cardioverting functions in a single implanted device
US4693253A (en) * 1981-03-23 1987-09-15 Medtronic, Inc. Automatic implantable defibrillator and pacer
US4708145A (en) * 1982-06-01 1987-11-24 Medtronic, Inc. Sequential-pulse, multiple pathway defibrillation method
US4574807A (en) * 1984-03-02 1986-03-11 Carl Hewson Method and apparatus for pacing the heart employing external and internal electrodes
US4825871A (en) * 1984-03-27 1989-05-02 Societe Anonyme Dite: Atesys Defibrillating or cardioverting electric shock system including electrodes
US4683890A (en) * 1985-12-23 1987-08-04 Brunswick Manufacturing Co., Inc. Method and apparatus for controlled breathing employing internal and external electrodes
US4834100A (en) * 1986-05-12 1989-05-30 Charms Bernard L Apparatus and method of defibrillation
US4768512A (en) * 1986-05-13 1988-09-06 Mieczyslaw Mirowski Cardioverting system and method with high-frequency pulse delivery
US5156148A (en) * 1987-10-06 1992-10-20 Leonard Bloom System for treating a malfunctioning heart
EP0326290A1 (en) * 1988-01-19 1989-08-02 Telectronics N.V. Method and apparatus for applying asymmetric biphasic truncated exponential countershocks
US5083562A (en) * 1988-01-19 1992-01-28 Telectronics Pacing Systems, Inc. Method and apparatus for applying asymmetric biphasic truncated exponential countershocks
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5389069A (en) * 1988-01-21 1995-02-14 Massachusetts Institute Of Technology Method and apparatus for in vivo electroporation of remote cells and tissue
US5667491A (en) * 1988-01-21 1997-09-16 Massachusetts Institute Of Technology Method for rapid temporal control of molecular transport across tissue
US5547467A (en) * 1988-01-21 1996-08-20 Massachusettes Institute Of Technology Method for rapid temporal control of molecular transport across tissue
DE3914662A1 (en) * 1989-05-03 1990-11-08 Alt Eckhard DEVICE FOR TRANSMITTING ELECTRICAL SIGNALS BETWEEN AN IMPLANTABLE MEDICAL DEVICE AND ELECTRICALLY EXPENSIBLE HUMAN TISSUE
US5083563A (en) * 1990-02-16 1992-01-28 Telectronics Pacing Systems, Inc. Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker
US6280462B1 (en) 1990-04-25 2001-08-28 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US5916238A (en) * 1990-04-25 1999-06-29 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US6999814B2 (en) 1990-04-25 2006-02-14 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US7522959B2 (en) 1990-04-25 2009-04-21 Cardiac Pacemakers, Inc. Subcutaneous cardiac rhythm management
US6157860A (en) * 1990-04-25 2000-12-05 Cardiac Pacemakers, Inc. Implantable intravenous cardiac stimulation system with pulse generator housing serving as optional additional electrode
US5105810A (en) * 1990-07-24 1992-04-21 Telectronics Pacing Systems, Inc. Implantable automatic and haemodynamically responsive cardioverting/defibrillating pacemaker with means for minimizing bradycardia support pacing voltages
US5184614A (en) * 1990-10-19 1993-02-09 Telectronics Pacing Systems, Inc. Implantable haemodynamically responsive cardioverting/defibrillating pacemaker
US5282837A (en) * 1991-04-12 1994-02-01 Incontrol, Inc. Atrial defibrillator and method
US5433729A (en) * 1991-04-12 1995-07-18 Incontrol, Inc. Atrial defibrillator, lead systems, and method
US5342403A (en) * 1993-04-09 1994-08-30 Hewlett-Packard Corporation Integrated defibrillator/monitor architecture with defibrillator-only fail-safe mode of operation
US5507778A (en) * 1994-02-22 1996-04-16 Zmd Corporation Semiautomatic defibrillator with synchronized shock delivery
US5391187A (en) * 1994-02-22 1995-02-21 Zmd Corporation Semiautomatic defibrillator with heart rate alarm driven by shock advisory algorithm
US5409009A (en) * 1994-03-18 1995-04-25 Medtronic, Inc. Methods for measurement of arterial blood flow
US5983131A (en) * 1995-08-11 1999-11-09 Massachusetts Institute Of Technology Apparatus and method for electroporation of tissue
US5738105A (en) * 1995-10-24 1998-04-14 Angeion Corporation Method and apparatus for sensing R-waves using both near field and far field sensing simultaneously
US6041256A (en) * 1996-03-01 2000-03-21 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter
US7366574B2 (en) 1996-03-01 2008-04-29 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter
US5913887A (en) * 1996-03-01 1999-06-22 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter including three coil electrodes
US20040193240A1 (en) * 1996-03-01 2004-09-30 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter
US6438416B1 (en) 1996-03-01 2002-08-20 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter including three coil electrodes
US6741894B2 (en) 1996-03-01 2004-05-25 Cardiac Pacemakers, Inc. Device for the transvenous cardioversion of atrial fibrillation or atrial flutter
US5911223A (en) * 1996-08-09 1999-06-15 Massachusetts Institute Of Technology Introduction of modifying agents into skin by electroporation
US6085115A (en) * 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US6501994B1 (en) 1997-12-24 2002-12-31 Cardiac Pacemakers, Inc. High impedance electrode tip
US7392095B2 (en) 1998-07-22 2008-06-24 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US8285398B2 (en) 1998-07-22 2012-10-09 Cardiac Pacemakers, Inc. Lead with terminal connector assembly
US6505082B1 (en) 1998-07-22 2003-01-07 Cardiac Pacemakers, Inc. Single pass lead system
US8209035B2 (en) 1998-07-22 2012-06-26 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US6212434B1 (en) 1998-07-22 2001-04-03 Cardiac Pacemakers, Inc. Single pass lead system
US6345204B1 (en) 1998-07-22 2002-02-05 Cardiac Pacemakers, Inc. Single pass lead having retractable, actively attached electrode for pacing and sensing
US6152954A (en) * 1998-07-22 2000-11-28 Cardiac Pacemakers, Inc. Single pass lead having retractable, actively attached electrode for pacing and sensing
US6915169B2 (en) 1998-07-22 2005-07-05 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US6983185B2 (en) 1998-07-22 2006-01-03 Cardiac Pacemakers, Inc. Lead with terminal connector assembly
US6321122B1 (en) 1998-07-22 2001-11-20 Cardiac Pacemakers, Inc. Single pass defibrillation/pacing lead with passively attached electrode for pacing and sensing
US6085119A (en) * 1998-07-22 2000-07-04 Cardiac Pacemakers, Inc. Single pass endocardial lead for multi-site atrial pacing
US7774934B2 (en) 1998-07-22 2010-08-17 Cardiac Pacemakers, Inc. Method for making a terminal connector
US6463334B1 (en) 1998-11-02 2002-10-08 Cardiac Pacemakers, Inc. Extendable and retractable lead
US6501990B1 (en) 1999-12-23 2002-12-31 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
US8568356B2 (en) 2000-01-21 2013-10-29 Medtronic Minimed, Inc. Ambulatory medical apparatus with hand held communication device
US9533096B2 (en) 2000-01-21 2017-01-03 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US7678071B2 (en) 2000-01-21 2010-03-16 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US7831310B2 (en) * 2000-01-21 2010-11-09 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
US20030176933A1 (en) * 2000-01-21 2003-09-18 Medtronic Minimed, Inc. Microprocessor controlled ambulatory medical apparatus with hand held communication device
EP2075014A2 (en) 2002-05-24 2009-07-01 Angiotech International Ag Compositions and methods for coating medical implants
US7239915B2 (en) 2003-12-16 2007-07-03 Medtronic, Inc. Hemodynamic optimization system for biventricular implants
US20050131469A1 (en) * 2003-12-16 2005-06-16 Leonard Bloom Hemodynamic optimization system for biventricular implants
US20070071685A1 (en) * 2003-12-22 2007-03-29 Bracco Research S.A. Gas-filled microvesicle assembly for contrast imaging
US8078287B2 (en) 2003-12-23 2011-12-13 Cardiac Pacemakers, Inc. His bundle mapping, pacing, and injection lead
US7245973B2 (en) 2003-12-23 2007-07-17 Cardiac Pacemakers, Inc. His bundle mapping, pacing, and injection lead
US8285376B2 (en) 2004-12-20 2012-10-09 Cardiac Pacemakers, Inc. Ventricular pacing
US8934969B2 (en) 2004-12-20 2015-01-13 Cardiac Pacemakers, Inc. Systems, devices and methods for monitoring efficiency of pacing
US9031648B2 (en) 2004-12-20 2015-05-12 Cardiac Pacemakers, Inc. Endocardial pacing devices and methods useful for resynchronization and defibrillation
US9008768B2 (en) 2004-12-20 2015-04-14 Cardiac Pacemakers, Inc. Methods, devices and systems for cardiac rhythm management using an electrode arrangement
US8903489B2 (en) 2004-12-20 2014-12-02 Cardiac Pacemakers, Inc. Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device
US8880169B2 (en) 2004-12-20 2014-11-04 Cardiac Pacemakers, Inc. Endocardial pacing relating to conduction abnormalities
US8838238B2 (en) 2004-12-20 2014-09-16 Cardiac Pacemakers, Inc. Ventricular pacing
US8825159B2 (en) 2004-12-20 2014-09-02 Cardiac Pacemakers, Inc. Devices and methods for steering electrical stimulation in cardiac rhythm management
US8812106B2 (en) 2004-12-20 2014-08-19 Cardiac Pacemakers, Inc. Apparatus for treating the physiological electric conduction of the heart
US8543203B2 (en) 2004-12-20 2013-09-24 Cardiac Pacemakers, Inc. Endocardial pacing devices and methods useful for resynchronization and defibrillation
US8538521B2 (en) 2004-12-20 2013-09-17 Cardiac Pacemakers, Inc. Systems, devices and methods for monitoring efficiency of pacing
US8437848B2 (en) 2004-12-20 2013-05-07 Cardiac Pacemakers, Inc. Apparatus for treating the physiological electric conduction of the heart
US8428715B2 (en) 2004-12-20 2013-04-23 Cardiac Pacemakers, Inc. Methods for treating the physiological electric conduction of the heart
US8423139B2 (en) 2004-12-20 2013-04-16 Cardiac Pacemakers, Inc. Methods, devices and systems for cardiac rhythm management using an electrode arrangement
US8346358B2 (en) 2004-12-20 2013-01-01 Cardiac Pacemakers, Inc. Pacemaker which reestablishes or keeps the physiological electric conduction of the heart and a method of application
US8326423B2 (en) 2004-12-20 2012-12-04 Cardiac Pacemakers, Inc. Devices and methods for steering electrical stimulation in cardiac rhythm management
US8290586B2 (en) 2004-12-20 2012-10-16 Cardiac Pacemakers, Inc. Methods, devices and systems for single-chamber pacing using a dual-chamber pacing device
US7775215B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. System and method for determining implanted device positioning and obtaining pressure data
US7775966B2 (en) 2005-02-24 2010-08-17 Ethicon Endo-Surgery, Inc. Non-invasive pressure measurement in a fluid adjustable restrictive device
US8016744B2 (en) 2005-02-24 2011-09-13 Ethicon Endo-Surgery, Inc. External pressure-based gastric band adjustment system and method
US7658196B2 (en) 2005-02-24 2010-02-09 Ethicon Endo-Surgery, Inc. System and method for determining implanted device orientation
US8016745B2 (en) 2005-02-24 2011-09-13 Ethicon Endo-Surgery, Inc. Monitoring of a food intake restriction device
US8066629B2 (en) 2005-02-24 2011-11-29 Ethicon Endo-Surgery, Inc. Apparatus for adjustment and sensing of gastric band pressure
US7927270B2 (en) 2005-02-24 2011-04-19 Ethicon Endo-Surgery, Inc. External mechanical pressure sensor for gastric band pressure measurements
US20110009641A1 (en) * 2005-06-15 2011-01-13 Anderson Daniel G Amine-containing lipids and uses thereof
US9006487B2 (en) 2005-06-15 2015-04-14 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
US8870742B2 (en) 2006-04-06 2014-10-28 Ethicon Endo-Surgery, Inc. GUI for an implantable restriction device and a data logger
US8152710B2 (en) 2006-04-06 2012-04-10 Ethicon Endo-Surgery, Inc. Physiological parameter analysis for an implantable restriction device and a data logger
US8187163B2 (en) 2007-12-10 2012-05-29 Ethicon Endo-Surgery, Inc. Methods for implanting a gastric restriction device
US8100870B2 (en) 2007-12-14 2012-01-24 Ethicon Endo-Surgery, Inc. Adjustable height gastric restriction devices and methods
US8377079B2 (en) 2007-12-27 2013-02-19 Ethicon Endo-Surgery, Inc. Constant force mechanisms for regulating restriction devices
US8142452B2 (en) 2007-12-27 2012-03-27 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8337389B2 (en) 2008-01-28 2012-12-25 Ethicon Endo-Surgery, Inc. Methods and devices for diagnosing performance of a gastric restriction system
US8591395B2 (en) 2008-01-28 2013-11-26 Ethicon Endo-Surgery, Inc. Gastric restriction device data handling devices and methods
US8192350B2 (en) 2008-01-28 2012-06-05 Ethicon Endo-Surgery, Inc. Methods and devices for measuring impedance in a gastric restriction system
US8221439B2 (en) 2008-02-07 2012-07-17 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using kinetic motion
US7844342B2 (en) 2008-02-07 2010-11-30 Ethicon Endo-Surgery, Inc. Powering implantable restriction systems using light
US8114345B2 (en) 2008-02-08 2012-02-14 Ethicon Endo-Surgery, Inc. System and method of sterilizing an implantable medical device
US8057492B2 (en) 2008-02-12 2011-11-15 Ethicon Endo-Surgery, Inc. Automatically adjusting band system with MEMS pump
US8591532B2 (en) 2008-02-12 2013-11-26 Ethicon Endo-Sugery, Inc. Automatically adjusting band system
US8034065B2 (en) 2008-02-26 2011-10-11 Ethicon Endo-Surgery, Inc. Controlling pressure in adjustable restriction devices
US8187162B2 (en) 2008-03-06 2012-05-29 Ethicon Endo-Surgery, Inc. Reorientation port
US8233995B2 (en) 2008-03-06 2012-07-31 Ethicon Endo-Surgery, Inc. System and method of aligning an implantable antenna
US10844028B2 (en) 2008-11-07 2020-11-24 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US10189802B2 (en) 2008-11-07 2019-01-29 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8969353B2 (en) 2008-11-07 2015-03-03 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US11414393B2 (en) 2008-11-07 2022-08-16 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US9556110B2 (en) 2008-11-07 2017-01-31 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
US8688234B2 (en) 2008-12-19 2014-04-01 Cardiac Pacemakers, Inc. Devices, methods, and systems including cardiac pacing
US10576166B2 (en) 2009-12-01 2020-03-03 Translate Bio, Inc. Liver specific delivery of messenger RNA
US8565880B2 (en) 2010-04-27 2013-10-22 Cardiac Pacemakers, Inc. His-bundle capture verification and monitoring
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
US10933139B2 (en) 2011-03-28 2021-03-02 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US10117934B2 (en) 2011-03-28 2018-11-06 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9597413B2 (en) 2011-06-08 2017-03-21 Shire Human Genetic Therapies, Inc. Pulmonary delivery of mRNA
US11338044B2 (en) 2011-06-08 2022-05-24 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11730825B2 (en) 2011-06-08 2023-08-22 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11547764B2 (en) 2011-06-08 2023-01-10 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11291734B2 (en) 2011-06-08 2022-04-05 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11185595B2 (en) 2011-06-08 2021-11-30 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11052159B2 (en) 2011-06-08 2021-07-06 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US9308281B2 (en) 2011-06-08 2016-04-12 Shire Human Genetic Therapies, Inc. MRNA therapy for Fabry disease
US10888626B2 (en) 2011-06-08 2021-01-12 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10507249B2 (en) 2011-06-08 2019-12-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10238754B2 (en) 2011-06-08 2019-03-26 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US10413618B2 (en) 2011-06-08 2019-09-17 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US10350303B1 (en) 2011-06-08 2019-07-16 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery
US11254936B2 (en) 2012-06-08 2022-02-22 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
US11510937B2 (en) 2013-03-14 2022-11-29 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US9957499B2 (en) 2013-03-14 2018-05-01 Translate Bio, Inc. Methods for purification of messenger RNA
US9713626B2 (en) 2013-03-14 2017-07-25 Rana Therapeutics, Inc. CFTR mRNA compositions and related methods and uses
US11820977B2 (en) 2013-03-14 2023-11-21 Translate Bio, Inc. Methods for purification of messenger RNA
US11692189B2 (en) 2013-03-14 2023-07-04 Translate Bio, Inc. Methods for purification of messenger RNA
US9181321B2 (en) 2013-03-14 2015-11-10 Shire Human Genetic Therapies, Inc. CFTR mRNA compositions and related methods and uses
US10420791B2 (en) 2013-03-14 2019-09-24 Translate Bio, Inc. CFTR MRNA compositions and related methods and uses
US10876104B2 (en) 2013-03-14 2020-12-29 Translate Bio, Inc. Methods for purification of messenger RNA
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
US10052284B2 (en) 2013-10-22 2018-08-21 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US9522176B2 (en) 2013-10-22 2016-12-20 Shire Human Genetic Therapies, Inc. MRNA therapy for phenylketonuria
US9629804B2 (en) 2013-10-22 2017-04-25 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger RNA
US10959953B2 (en) 2013-10-22 2021-03-30 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US11890377B2 (en) 2013-10-22 2024-02-06 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US11224642B2 (en) 2013-10-22 2022-01-18 Translate Bio, Inc. MRNA therapy for argininosuccinate synthetase deficiency
US10493031B2 (en) 2013-10-22 2019-12-03 Translate Bio, Inc. Lipid formulations for delivery of messenger RNA
US10155785B2 (en) 2014-04-25 2018-12-18 Translate Bio, Inc. Methods for purification of messenger RNA
US9850269B2 (en) 2014-04-25 2017-12-26 Translate Bio, Inc. Methods for purification of messenger RNA
US11884692B2 (en) 2014-04-25 2024-01-30 Translate Bio, Inc. Methods for purification of messenger RNA
US11059841B2 (en) 2014-04-25 2021-07-13 Translate Bio, Inc. Methods for purification of messenger RNA
US11433144B2 (en) 2014-05-30 2022-09-06 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10912844B2 (en) 2014-05-30 2021-02-09 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10022455B2 (en) 2014-05-30 2018-07-17 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10286082B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10286083B2 (en) 2014-05-30 2019-05-14 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10493166B2 (en) 2014-05-30 2019-12-03 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10293057B2 (en) 2014-05-30 2019-05-21 Translate Bio, Inc. Biodegradable lipids for delivery of nucleic acids
US10138213B2 (en) 2014-06-24 2018-11-27 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US11104652B2 (en) 2014-06-24 2021-08-31 Translate Bio, Inc. Stereochemically enriched compositions for delivery of nucleic acids
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
US11253605B2 (en) 2017-02-27 2022-02-22 Translate Bio, Inc. Codon-optimized CFTR MRNA
US11173190B2 (en) 2017-05-16 2021-11-16 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
US11951180B2 (en) 2023-04-03 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11951179B2 (en) 2023-04-03 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for MRNA delivery
US11951181B2 (en) 2023-04-03 2024-04-09 Translate Bio, Inc. Lipid nanoparticle compositions and methods for mRNA delivery

Also Published As

Publication number Publication date
CA981338A (en) 1976-01-06

Similar Documents

Publication Publication Date Title
US3614955A (en) Standby defibrillator and method of operation
US3614954A (en) Electronic standby defibrillator
USRE27757E (en) Standby defibrillator and method of operation
US3942536A (en) Cardioverting device having single intravascular catheter electrode system and method for its use
USRE27652E (en) Electronic standby defibrillator
US4403614A (en) Implantable cardioverter
EP0009255B1 (en) An automatic cardiac ventricular defibrillator
US3805795A (en) Automatic cardioverting circuit
US4375817A (en) Implantable cardioverter
US4693253A (en) Automatic implantable defibrillator and pacer
US5527345A (en) Implantable atrial defibrillator having an intermittenly activated pacing modality
USRE30387E (en) Automatic cardioverting circuit
US4210149A (en) Implantable cardioverter with patient communication
US5549646A (en) Periodic electrical lead intergrity testing system and method for implantable cardiac stimulating devices
EP0576109B1 (en) Pulse generator for use in an implantable atrial defibrillator
JP4347059B2 (en) Method and apparatus for preventing early recurrence of atrial fibrillation using atrial pacing
US5348021A (en) Apparatus and method for reliably detecting a depolarization activation wave of the heart and atrial defibrillator utilizing same
US5269301A (en) Multimode system for monitoring and treating a malfunctioning heart
EP0488512B1 (en) Implantable haemodynamically responsive cardioverting/defibrillating pacemaker
JP4782374B2 (en) System and method for continuously applying low energy defibrillation pulses
US5464432A (en) Implantable atrial defibrillator having an intermittently activated fibrillation detector
USRE30372E (en) Automatic cardioverting circuit
JPH01212572A (en) Method and apparatus for treatment cardiac insufficiency reacting hemodynamically
US6068651A (en) Atrial defibrillation lock out feature
US5571141A (en) Device and method for cardiac arrhythmia therapy with failure detection and backup